These specifications describe the tasks and requirements for the GMP production of a fixed dose combination of Artesunate + Pyronaridine + Sulfadoxine + Pyrimethamine for the use in a phase II - III clinical trial. Details for each individual task are listed below. All available supportive information for the conduction of the work will be shared with the manufacturer under a non-disclosure agreement.